Biotechnology News and Research

RSS

Oragenics signs distribution agreement with RICCI PHARMA

Florida-based biotechnology company Oragenics, Inc., and RICCI PHARMA, a recognized health products company with offices in Rome and Slovakia, have entered into a distribution agreement that the parties anticipate will provide Oragenics' proprietary oral care probiotic products, EvoraPlus® and EvoraKidsTM, to RICCI PHARMA. RICCI PHARMA will have exclusive distribution rights through Duc in Altum, a foundation whose humanitarian projects are inspired by the social teachings of the late Pope John Paul II.

13 Apr 2010

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

Aeolus Pharmaceuticals, Inc. announced today that a second study of its lead drug, AEOL 10150, has been initiated by the National Institutes of Health's (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal (GI) tract.

13 Apr 2010

Article One Partners concludes AUTO Patent Studies

Article One Partners, the world's largest patent validation firm, today announced the conclusion of two Patent Studies conducted on behalf of a top global automaker, for which $30,000 has been awarded to two Advisors.

13 Apr 2010

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Talecris Biotherapeutics, Inc., today announced results of a new survey showing that Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) is the preferred immune globulin intravenous (IGIV) among neurologists who indicated a brand preference. In the survey, conducted online by Harris Interactive® on behalf of Talecris, neurologists selected Gamunex over four times more often than all other available liquid IGIV therapies, with a statistically significant margin (p<0.05).

13 Apr 2010

Cytomedix reports going concern qualification in Annual Report for fiscal year ended December 31, 2009

Cytomedix, Inc. announced today that its audited financial statements for the fiscal year ended December 31, 2009, included in its Annual Report on Form 10-K filed on March 29, 2010, contained a going concern qualification from its independent registered accounting firm.

13 Apr 2010

Bio-Bridge Science granted Japanese patent covering use of papilloma pseudovirus

Bio-Bridge Science, Inc., a biotechnology company engaged in the commercial development of vaccines and vaccine-related products announced today that the Japanese Patent Office has granted claims in a patent application, and issued a Patent Number 4472724, regarding the use of the papilloma pseudovirus.

13 Apr 2010

Cytomedix to acquire Sorin's Angel blood separation system and activAT Autologous Thrombin Processing Kit

Cytomedix, Inc., a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced the closing of an agreement with Sorin Group, a global leader in the treatment of cardiovascular diseases, to acquire the Angel® Whole Blood Separation System and activAT® Autologous Thrombin Processing Kit for $7 million in cash, to be paid in installments over the next two and one-half years.

13 Apr 2010

RXi Pharmaceuticals, Mirna Therapeutics form microRNA research collaboration

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.

12 Apr 2010

FDA approves Mylan Pharmaceuticals' ANDA for generic Hyzaar

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Losartan Potassium and Hydrochlorothiazide (HCTZ) Tablets 100 mg/12.5 mg, the generic version of Merck and Co., Inc.'s antihypertensive Hyzaar®.

12 Apr 2010

CPEX Pharmaceuticals files definitive proxy materials with SEC, mails open letter to shareholders

CPEX Pharmaceuticals, Inc. today announced that it has filed definitive proxy materials with the Securities and Exchange Commission (SEC) for its 2010 Annual Meeting of Stockholders. The Company has nominated Robert Forrester, a highly qualified independent director candidate, for election to the Board of Directors at the meeting.

12 Apr 2010

Angiochem to highlight oncology program data at 101st American Association for Cancer Research meeting

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP targeting, announced today that preclinical data on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers, as well as data demonstrating the utility of Angiochem's EPiC platform to achieve efficient penetration rates in the brain and in cancer tumor tissue, will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010.

12 Apr 2010

Carestream Molecular Imaging, OncoVision sign exclusive agreement for Albira PET/SPECT/CT imaging system

Carestream Molecular Imaging, a division of Carestream Health, Inc., has signed an exclusive, multi-year worldwide agreement with OncoVision (Valencia, Spain), to sell, market and service the Albira PET/SPECT/CT imaging system for small animal research. With the addition of this innovative, multimodal imaging system, Carestream Molecular Imaging will offer the broadest portfolio of pre-clinical in vivo imaging modalities in the market.

12 Apr 2010

FDA approves Sinapis Pharma's IND for IV methamphetamine in treatment of acute stroke

Sinapis Pharma is pleased to announce that it has received notice from the FDA that its Investigational New Drug application (IND) for the use of IV methamphetamine for acute stroke was approved on April 9, 2010. "We have accomplished a great deal of work for a small company on a very tight budget. We have GMP drug ready for the Phase I clinical trial and the Phase I site is prepared to begin this protocol," said Dr. Donald Picker , the company CEO.

12 Apr 2010

Medinox, Orient Europharma form partnering agreement for NOX-100 anti-hypotensive drug

Medinox, Inc. in Carlsbad, California and Orient Europharma in Taiwan announce today that they have entered into a partnering agreement to develop and market NOX-100, a new anti-hypotensive drug. Under the terms of the agreement, Orient Europharma holds the exclusive distribution rights of NOX-100 in Taiwan, China, Korea, Australia, New Zealand and Southeast Asia. Medinox retains the marketing rights in the United States, Japan and Europe.

12 Apr 2010

Vivakor board approve dividend for Regeneca International

Vivakor, Inc. announced today that its Board of Directors approved a dividend of shares of common stock of Regeneca International, Inc.. Vivakor previously received the shares from Regeneca in the fourth quarter of 2009 under a license agreement whereby Vivakor exclusively licensed to Regeneca, for the direct to consumer market, distribution rights to RegeneBlend, one of the new cutting-edge nutraceutical formulations developed by Vivakor.

12 Apr 2010

CoreLab Partners' new logo and brand identity launched

CoreLab Partners, Inc, the recently established global entity resulting from the merger between RadPharm and Medifacts International, has launched a new brand identity to reinforce their capabilities as one of the largest imaging sciences and cardiac safety core labs in the market today.

12 Apr 2010

Clinical and preclinical malaria vaccine data presented at Keystone Symposium

GenVec, Inc. announced that encouraging clinical and preclinical malaria vaccine data were presented at the Keystone Symposium -- Malaria: New Approaches to Understanding Host-Parasite Interactions taking place April 11-16, 2010 in Copper Mountain, Colorado.

12 Apr 2010

Scientists identify specific mechanism that triggers resistance to vancomycin

A new study led by the scientific director of the Michael G. DeGroote Institute for Infectious Disease Research has uncovered for the first time how bacteria recognize and develop resistance to a powerful antibiotic used to treat superbug infections.

12 Apr 2010

Researchers investigate effects of nanoparticles on yeast

Nanoparticles are already widely used in everyday products such as cosmetics, textiles, dyes, and paints. It is quite possible that these minute fragments of matter may in future not only come to play a crucial role in medicine and pharmacology, but also in the food and biotechnology industries. The latest research currently being conducted in India has shown that nanoparticles can promote the growth of fungi and even assist plant growth.

12 Apr 2010

Resverlogix highlights features of RVX-208 drug at ATVB conference

Resverlogix Corp. announced today that key scientific data was communicated in an oral presentation highlighting the novel features of RVX-208, the Company's lead drug, during the Atherosclerosis, Thrombosis, Vascular Biology conference being held in San Francisco, California.

12 Apr 2010

Biotechnology News and Research

Oragenics signs distribution agreement with RICCI PHARMA

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

Article One Partners concludes AUTO Patent Studies

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Cytomedix reports going concern qualification in Annual Report for fiscal year ended December 31, 2009

Bio-Bridge Science granted Japanese patent covering use of papilloma pseudovirus

Cytomedix to acquire Sorin's Angel blood separation system and activAT Autologous Thrombin Processing Kit

RXi Pharmaceuticals, Mirna Therapeutics form microRNA research collaboration

FDA approves Mylan Pharmaceuticals' ANDA for generic Hyzaar

CPEX Pharmaceuticals files definitive proxy materials with SEC, mails open letter to shareholders

Angiochem to highlight oncology program data at 101st American Association for Cancer Research meeting

Carestream Molecular Imaging, OncoVision sign exclusive agreement for Albira PET/SPECT/CT imaging system

FDA approves Sinapis Pharma's IND for IV methamphetamine in treatment of acute stroke

Medinox, Orient Europharma form partnering agreement for NOX-100 anti-hypotensive drug

Vivakor board approve dividend for Regeneca International

CoreLab Partners' new logo and brand identity launched

Clinical and preclinical malaria vaccine data presented at Keystone Symposium

Scientists identify specific mechanism that triggers resistance to vancomycin

Researchers investigate effects of nanoparticles on yeast

Resverlogix highlights features of RVX-208 drug at ATVB conference

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News